The life-or-death mystery confounded Dr. Jennifer Woyach, whose team faced a puzzling setback involving a breakthrough drug that had stopped working in some patients with chronic lymphocytic leukemia (CLL).
That drug, called ibrutinib, had been developed largely through basic and clinical research by physicians and scientists at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), and it…
